Genelux Corporation

Dec 11, 2020

V2ACT Therapeutics(TM), LLC Announces FDA Clearance of an IND Application to proceed with a Phase 1/2a Study of V2ACT for the Treatment of Pancreatic Cancer

Sep 16, 2020

Genelux to Present Data from Phase 2 Trial of Olvi-Vec in Heavily Pre-treated Platinum-Resistant/Refractory Ovarian Cancer at ESMO Virtual Congress 2020

Sep 10, 2020

Genelux Announces Oral Plenary Presentation of VIRO-15 Phase 2 Trial Data at the 2020 xDigital Annual Global Meeting of the International Gynecologic Cancer Society

Jun 04, 2020

Genelux Announces Formation of Clinical Advisory Board on Gynecologic Cancers